Skip to main navigation

Skip to content

Menu

Home
About
Baxdrostat
Pipeline
Investors
Contact

INVESTORS >> News Releases

Year

News Release

August 31, 2022

CinCor Pharma to Participate at Upcoming September Investor Conferences

News Release

August 22, 2022

CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress

News Release

August 15, 2022

CinCor Pharma Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

News Release

August 11, 2022

CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

News Release

August 8, 2022

CinCor Pharma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

News Release

August 8, 2022

CinCor Reports Second Quarter Financial Results and Provides Corporate Update

News Release

August 8, 2022

CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension

News Release

July 26, 2022

CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension

News Release

June 1, 2022

CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease

News Release

May 31, 2022

CinCor Pharma to Present at the Jefferies Healthcare Conference

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20

Email Alerts
Contact Us
RSS Feeds

Home
About
Baxdrostat
Pipeline
Investors
Contact

© 2022 CinCor. All rights reserved

Privacy
LinkedIn
Twitter